Related Experiment Video
Updated: Jun 30, 2026
Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
Progress in siRNA therapy and delivery platforms for osteoarthritis
Shitang Song1,2, Wei Liu1,2, Siqi Wang3
1Sports Medicine Department, Beijing Key Laboratory of Sports Injuries, Peking University Third Hospital, Beijing 100191, P.R. China.
Abstract:
Osteoarthritis (OA) is driven by a cycle of cartilage decay, synovial inflammation, and bone remodeling. This progression is fueled by the self-perpetuating synergy between matrix-degrading enzymes and pro-inflammatory cytokines, posing a formidable barrier to effective therapy. Small interfering RNAs (siRNAs) offer a transformative precision medicine paradigm, harnessing the RNA interference (RNAi) machinery to silence pathogenic drivers. However, their clinical application hinges on navigating the complex intra-articular microenvironment. This review synthesizes current progress in siRNA delivery architectures, spanning viral vectors, lipidic nanoplatforms, polymeric assemblies, and hybrid biomimetic systems. The spatiotemporal retention and intracellular bioavailability of siRNAs have been augmented by key engineering breakthroughs, including ligand-mediated active targeting, precise surface topography tuning, and integrated stimulus-responsive functionalities. This review, by exploring future directions like multi-target silencing and the use of large animal models relevant to clinical practice, highlights how siRNA-based treatments are moving beyond experimental ideas to applications as real anti-OA drugs.
Insights
Osteoarthritis (OA) treatments are advancing with small interfering RNAs (siRNAs). Engineering novel delivery systems enhances siRNA efficacy for targeting cartilage decay and inflammation, paving the way for new OA therapies.
Area of Science:
- Biomedical Engineering
- Molecular Medicine
- Rheumatology
Background:
- Osteoarthritis (OA) involves cartilage degradation, synovial inflammation, and bone remodeling.
- A cycle of matrix-degrading enzymes and pro-inflammatory cytokines drives OA progression.
- Effective OA therapies face challenges due to the complex intra-articular environment.
Purpose of the Study:
- To review current progress in small interfering RNA (siRNA) delivery systems for OA treatment.
- To explore engineering breakthroughs enhancing siRNA spatiotemporal retention and bioavailability.
- To discuss future directions for siRNA-based OA therapeutics.
Main Methods:
- Synthesis of current research on siRNA delivery architectures (viral, lipidic, polymeric, hybrid).
- Analysis of engineering strategies for improved siRNA targeting and cellular uptake.
- Exploration of advanced concepts like multi-target silencing and large animal models.
Main Results:
- Various siRNA delivery platforms show promise for intra-articular application.
- Engineering strategies significantly improve siRNA retention and bioavailability within the joint.
- Ligand-mediated targeting, surface tuning, and responsive systems enhance therapeutic potential.
Conclusions:
- siRNA delivery systems are advancing beyond experimental stages for OA.
- Engineered nanoplatforms offer a precision medicine approach to combat OA.
- Future research directions aim to translate these advancements into clinical OA treatments.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...